CDEK
← All drugs Report issue

humanised anti-cd22 antibody

mAbexperimental

Clinical trial activity

37 trials · 22 clinical orgs · 0 marketing orgs

Phase 1
13
Phase 2
31
Phase 3
10
Phase 4
0

Earliest trial started Mar 1, 1997 (NCT00003338)

Timeline

1990s

  1. Jan 1, 1997

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 1997

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 1997

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 90y-epratuzumab
  • 90y_hll2
  • 90y-hll2
  • 99mtc epratuzumab
  • amg-412
  • anti-cd22 igg
  • epratuzumab
  • epratuzumab
  • epratuzumab
  • epratuzumab
  • epratuzumab
  • hll2
  • hll2 agent
  • humanised anti-cd22 antibody
  • immu-hll2
  • lymphocide
  • lymphocide
  • y90 epratuzumab
  • yttrium y 90 epratuzumab

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02577094Phase 1/Phase 2 (Phase 2)Oct 2, 2015Immunomedics, Institut de Cancerologie de l'Ouest Paul Papin, University of Nantes
NCT02306629Phase 1Nov 1, 2014ACM Global Laboratories, Eurofins, Hoosier Cancer Research Network, Pharmaceutical Research Associates, Inc. (PRA), Richmond Pharmacology
NCT01802814Phase 3May 1, 2014University Hospital of Berlin
NCT01534403Phase 2Jan 1, 2012Hoosier Cancer Research Network
NCT01449071Phase 1/Phase 2 (Phase 2)Oct 1, 2011Hoosier Cancer Research Network
NCT01408576Phase 3Jul 1, 2011Hoosier Cancer Research Network
NCT01261793Phase 3Dec 1, 2010Hoosier Cancer Research Network
NCT01262365Phase 3Dec 1, 2010Hoosier Cancer Research Network
NCT01219816Phase 2Nov 1, 2010University of Nantes
NCT01354457Phase 1/Phase 2 (Phase 2)Nov 1, 2010University of Nantes
NCT00945815Phase 2Sep 1, 2010National Cancer Institute (NCI), Southwest Oncology Group, University of Rochester
NCT01279707Phase 1/Phase 2 (Phase 2)Jan 1, 2010Immunomedics, University of London
NCT00941928Phase 2Jul 1, 2009University of Texas at Houston
NCT00660881Phase 2May 1, 2008Hoosier Cancer Research Network
NCT00553501Phase 2Mar 1, 2008National Cancer Institute (NCI), University of Vermont
NCT00624351Phase 2Jan 1, 2008Hoosier Cancer Research Network
NCT00382837Phase 3Jan 1, 2007Hoosier Cancer Research Network
NCT00383513Phase 2Jun 1, 2006Hoosier Cancer Research Network
NCT00301821Phase 2Jan 1, 2006Mayo Clinic, National Cancer Institute (NCI)
NCT00111306Phase 3Jun 1, 2005Hoosier Cancer Research Network
Showing 20 of 37 trials
Page 1 / 2

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hoosier Cancer Research NetworkAcademic/Hospital131332005
ImmunomedicsFor profit8631997
National Cancer Institute (NCI)Government8321998
Garden State Cancer CenterAcademic/Hospital3321997
University of NantesAcademic/Hospital3312010
AmgenFor profit2122000
University of California, Los AngelesAcademic/Hospital2222001
ACM Global LaboratoriesFor profit1012014
EurofinsFor profit1012014
Institut de Cancerologie de l'Ouest Paul PapinAcademic/Hospital1012015
Mayo ClinicAcademic/Hospital1012006
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Government1112001
National Institutes of Health (NIH)Government1012000
Pharmaceutical Research Associates, Inc. (PRA)For profit1012014
Richmond PharmacologyFor profit1012014
Southwest Oncology GroupAcademic/Hospital1112010
Stanford UniversityAcademic/Hospital1112000
University Hospital of BerlinAcademic/Hospital1112014
University of LondonAcademic/Hospital1112010
University of RochesterAcademic/Hospital1012010
22 organizations
Page 1 / 2